|Glioma Prognostic Subtyping - Astrocytoma, Oligodendroglioma, Meningioma, and Glioblastoma using New miRNA Biomarker Panel
Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit
Malignant gliomas are extremely aggressive and lethal form of brain tumors. Despite considerable advances in surgery, radiotherapy and chemotherapy, the prognosis for patients with gliomas remains poor. Molecular markers for early detection are fundamental to develop targeted treatments and to improve the outcome for patients with glioma. microRNAs (miRNAs) are a group of small, endogenous, noncoding RNA molecules that regulate a wide spectrum of gene expression in a posttranscriptional manner. Altered expressions of miRNAs have been associated with various malignancies including brain tumors. As a promising therapeutic tool against malignant gliomas, miRNAs have attracted increasing attention in recent years. In situ hybridization (ISH) technique with variant probe design or signal amplification allows direct assessment of miRNA expression within formalin-fixed, paraffin-embedded (FFPE) tissue. By using this method, the miRNA expression pattern in FFPE tumor tissue has been explored in many tumors.
BioGenex also has an extensive catalog of over 240 unique miRNA probes